Dasatinib (Sprycel)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:40, 13 May 2012 by Dryang (talk | contribs) (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

Also known as BMS-354825.

General information

Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Dasatinib (Sprycel) package insert
  2. ↑ Dasatinib (Sprycel) package insert (locally hosted backup)
  3. ↑ Dasatinib (Sprycel) patient drug information (Chemocare)
  4. ↑ Dasatinib (Sprycel) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Dasatinib_(Sprycel)&oldid=1476"